Product
Nab-paclitaxel
Aliases
ABI-007, Abraxane, Abraxane®, ABRAXANE®, Abraxane, nanoparticle albumin-bound paclitaxel, paclitaxel, ABI-007 (8 other aliases)
Name
albumin-bound paclitaxel
64 clinical trials
1 drug
2 abstracts
69 indications
Indication
Pancreatic CancerIndication
Solid TumorIndication
Solid TumoursIndication
CancerIndication
Advanced or Metastatic Solid TumorsIndication
Locally Advanced Solid TumorIndication
Metastatic Solid TumorIndication
cancerIndication
Squamous CellIndication
Ovarian CarcinomaIndication
Fallopian Tube NeoplasmsIndication
Peritoneal NeoplasmsIndication
Pancreatic AdenocarcinomaIndication
Metastatic Non-small Cell Lung CancerIndication
Pancreatic adenocarcinomaIndication
MetastaticIndication
Lung CancerIndication
lung cancerIndication
Non-Small-Cell Lung CancerIndication
Advanced GastrointestinalIndication
Biliary TractIndication
Pancreatic Ductal AdenocarcinomaIndication
Pancreatic Cancer MetastaticIndication
Stomach CancerIndication
Advanced Solid TumoursIndication
Advanced Solid TumorIndication
Breast CancerIndication
Small Cell Lung CancerIndication
Triple-negative Breast CancerIndication
Non-Small Cell LungIndication
Triple Negative Breast CancerIndication
Triple-Negative Breast CancerIndication
Colorectal CancerIndication
Esophageal CancerIndication
Esophageal adenocarcinomaIndication
Bile Duct CancerIndication
CholangiocarcinomaIndication
Metastatic CancerIndication
Hodgkin lymphomaIndication
lymphomaIndication
B-cellIndication
FollicularIndication
Large B-CellIndication
DiffuseIndication
MelanomaIndication
MetastasisIndication
Head and NeckIndication
Non-Small Cell Lung Cancer MetastaticIndication
Non-small Cell CarcinomaIndication
Squamous Cell CarcinomaIndication
Squamous Cell NeoplasmIndication
Non-HodgkinIndication
Squamous-Cell Non-Small-Cell Lung CancerIndication
triple-negative breast cancerIndication
Advanced CancerIndication
Metastatic MelanomaIndication
Pancreatic DuctalIndication
Advanced Solid TumorsIndication
pharmacokineticsIndication
Breast NeoplasmsIndication
Pancreatic Cancer Stage IIIIndication
OncologyIndication
Non-small-cell-lung-cancerIndication
Metastatic Solid TumorsIndication
Head and Neck Squamous Cell CarcinomaIndication
Gastroesophageal Junction AdenocarcinomaDrug
Nab-PaclitaxelIndication
Esophageal Squamous CarcinomaIndication
NSCLCClinical trial
A Multicenter, Open-label, ExploRatory Platform Trial to EValuate ImmunOtherapy Combinations With Chemotherapy for the Treatment of Patients With PreviousLy UnTreated MetastatIc Pancreatic AdenOcarciNoma (REVOLUTION)Status: Active (not recruiting), Estimated PCD: 2024-10-31
Clinical trial
A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Participants With Locally Advanced or Metastatic Solid TumoursStatus: Active (not recruiting), Estimated PCD: 2024-10-07
Clinical trial
An Open-label Phase 1b Study of ORIC-101 in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid TumorsStatus: Terminated, Estimated PCD: 2022-09-22
Clinical trial
A Randomized, Double-Blind, Phase 3 Study of MK-7684A in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2025-11-10
Clinical trial
A Phase I/II Clinical Study of TC-N201 Injection for the Treatment of Advanced Solid Tumors With HLA-A2 Expression and Positive NY-ESO-1.Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase 3, Multicenter, Randomized Open-Label Study to Compare the Efficacy and Safety of Tislelizumab (BGB A317, Anti-PD1 Antibody) Combined With Paclitaxel Plus Carboplatin or Nab Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Untreated Advanced Squamous Non-small Cell Lung CancerStatus: Completed, Estimated PCD: 2020-09-30
Clinical trial
A Phase 1 Clinical Study to Evaluate the Bioavailability of Pembrolizumab Via Subcutaneous Injection of MK-3475A, a Formulation of Pembrolizumab With MK-5180, in Participants With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2026-09-26
Clinical trial
A Phase 1b Study to Evaluate HMBD-001 With or Without Chemotherapy in Participants With Advanced Solid Tumors Harboring NRG1 Gene Fusions or Selected HER3 MutationsStatus: Recruiting, Estimated PCD: 2031-03-01
Clinical trial
A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal MalignanciesStatus: Active (not recruiting), Estimated PCD: 2027-05-01
Clinical trial
A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)Status: Active (not recruiting), Estimated PCD: 2023-09-21
Clinical trial
A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN)Status: Active (not recruiting), Estimated PCD: 2023-05-23
Clinical trial
A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-09-23
Clinical trial
A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the PancreasStatus: Active (not recruiting), Estimated PCD: 2022-07-23
Clinical trial
A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor AberrationsStatus: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic CancerStatus: Recruiting, Estimated PCD: 2025-04-28
Clinical trial
A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)Status: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletionStatus: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Randomized, Double-blind, Phase III Study, Comparing NIS793 in Combination With Gemcitabine and Nab-paclitaxel Versus (vs.) Placebo Combined With Gemcitabine and Nab-paclitaxel for First Line Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2Status: Active (not recruiting), Estimated PCD: 2024-06-28
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal AdenocarcinomaStatus: Recruiting, Estimated PCD: 2026-08-29
Clinical trial
A Phase Ib, Open-Label, Multicenter Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Patients With Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Phase Ib/II, Open-Label, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and Subsequently in Patients With Non-Small-Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2020-01-17
Clinical trial
A Phase 1b, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0482 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors.Status: Active (not recruiting), Estimated PCD: 2025-02-19
Clinical trial
A Phase III Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Neoadjuvant Anthracycline/Nab-Paclitaxel-Based Chemotherapy Compared With Placebo and Chemotherapy in Patients With Primary Invasive Triple-Negative Breast CancerStatus: Completed, Estimated PCD: 2020-04-03
Clinical trial
A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid TumorsStatus: Completed, Estimated PCD: 2023-01-31
Clinical trial
A Phase 1 Clinical Trial of CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Exocrine Pancreatic CancerStatus: Completed, Estimated PCD: 2020-06-19
Clinical trial
A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355)Status: Completed, Estimated PCD: 2021-06-15
Clinical trial
A Phase 2, Open-Label, Multi-Center Study to Assess Safety and Efficacy of Second/Third-Line Treatment With NAB®-Paclitaxel (ABI-007) In Combination With Epigenetic Modifying Therapy Of CC-486, Or Immunotherapy of Durvalumab (MEDI4736), Or As Monotherapy In Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC): Abound.2L+Status: Completed, Estimated PCD: 2017-07-17
Clinical trial
AdvanTIG-211: A Randomized, Double-blind, Placebo-controlled, Phase II Study Evaluating the Efficacy and Safety of Ociperlimab (WCD118) Combined With Tislelizumab (VDT482) Plus Chemotherapy Versus Placebo Combined With Pembrolizumab Plus Chemotherapy as First-line Therapy for Participants With Advanced Triple Negative Breast Cancer (TNBC)Status: Withdrawn, Estimated PCD: 2029-07-17
Clinical trial
An Open Label, Dose Escalation Followed by Dose Expansion, Safety and Tolerability Trial of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Subjects With Solid Malignant TumorsStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)Status: Completed, Estimated PCD: 2018-04-03
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding, Lead-in PhaseStatus: Terminated, Estimated PCD: 2017-04-10
Clinical trial
A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)Status: Completed, Estimated PCD: 2020-09-30
Clinical trial
A Multicenter, Open-Label, Randomized, Phase Ib/II Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of IN10018 Combined With Taxane and Anti-PD-1/L1 Monoclonal Antibody in Previously-treated Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced MalignanciesStatus: Terminated, Estimated PCD: 2023-03-06
Clinical trial
A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal AdenocarcinomaStatus: Completed, Estimated PCD: 2022-07-22
Clinical trial
A Phase Ib/II Study to Evaluate Efficacy, Safety and Tolerability of KN046 Monotherapy or in Combination With Nab-paclitaxel in Subjects With Triple-negative Breast CancerStatus: Completed, Estimated PCD: 2022-08-16
Clinical trial
Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid TumorsStatus: Terminated, Estimated PCD: 2023-07-24
Clinical trial
A Phase Ib, Open-Label, Multicohort Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Patients With Triple-Negative Breast CancerStatus: Completed, Estimated PCD: 2023-03-08
Clinical trial
A Multicenter, Open-Label, Phase I/II Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2022-05-16
Clinical trial
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Bemarituzumab Monotherapy and Combination With Other Anti-Cancer Therapy in Subjects With Squamous-Cell Non-Small-Cell Lung Cancer (FORTITUDE-201)Status: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
A Multi-center, Open-label Phase II Study to Evaluate the Safety and Efficacy of YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Patients With Unresectable/Metastatic Melanoma and Pancreatic Ductal Adenocarcinoma (PDAC)Status: Active (not recruiting), Estimated PCD: 2024-01-01
Clinical trial
A Phase 1 Multi-Targeted Study to Promote Anti-Tumor Immunity in ER Positive, HER2 Negative Advanced Breast CancerStatus: Completed, Estimated PCD: 2022-08-15
Clinical trial
A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced CancerStatus: Completed, Estimated PCD: 2021-02-10
Clinical trial
A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic CancerStatus: Completed, Estimated PCD: 2023-06-01
Clinical trial
AdvanTIG-306: A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Ociperlimab (WCD118/BGB-A1217) Combined With Tislelizumab (VDT482/BGB-A317) Plus Platinum-based Doublet Chemotherapy Versus Placebo Combined With Pembrolizumab Plus Platinum-based Doublet Chemotherapy as First-line Therapy for Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)Status: Withdrawn, Estimated PCD: 2027-12-24
Clinical trial
A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Subjects With Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaStatus: Completed, Estimated PCD: 2022-10-27
Clinical trial
A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic AdenocarcinomaStatus: Completed, Estimated PCD: 2020-03-01
Clinical trial
A Phase 1 Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-10-25
Clinical trial
A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2023-06-14
Clinical trial
Phase I Study of Combination With TBI-1401(HF10), a Replication-competent HSV-1 Oncolytic Virus, and Chemotherapy in Patients With Stage III or IV Unresectable Pancreatic Cancer.Status: Active (not recruiting), Estimated PCD: 2020-02-19
Clinical trial
A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic AdenocarcinomaStatus: Completed, Estimated PCD: 2020-06-01
Clinical trial
A Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Napabucasin ProtocolsStatus: Completed, Estimated PCD: 2021-05-15
Clinical trial
A Multicentre, Open-parallel, Randomized, Controlled Phase Ⅲ Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer.Status: Terminated, Estimated PCD: 2023-04-14
Clinical trial
A Randomized, Open Label, Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic CancerStatus: Completed, Estimated PCD: 2021-12-15
Clinical trial
A Phase Ib/II, Open-Label Study of M7824 in Combination With Chemotherapy in Participants With Stage IV Non-small Cell Lung CancerStatus: Completed, Estimated PCD: 2022-07-29
Clinical trial
A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects With Locally Advanced or Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-11-12
Clinical trial
A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (RELIANT)Status: Terminated, Estimated PCD: 2021-08-23
Clinical trial
Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2029-03-25
Clinical trial
An Umbrella Trial Based on Molecular Pathway for Patients With Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer (FUTURE SUPER)Status: Active (not recruiting), Estimated PCD: 2023-05-31
Clinical trial
Evaluation of the Efficacy and Safety of Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant and Conversion Therapy for Advanced Gastric Cancer (RNPLS-01)Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase II Study of FOLFOX Combined With Nab-Paclitaxel (FOLFOX-A) in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma. Big Ten Cancer Research Consortium: BTCRC-GI15-015Status: Completed, Estimated PCD: 2022-12-27
Clinical trial
Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer, a Small-scale, Exploratory Real-world StudyStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Phase 3, Prospective，Multicenter, Randomized Open-Label Trial to Compare the Efficacy and Safety of Tislelizumab (BGB A317, Anti-PD1 Antibody) Combined With Chemotherapy Followed By Surgery Versus Up-Front Surgery as Treatment for Resectable Head And Neck Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2028-10-01